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Abstract. Among the subsets of tumor‑infiltrating lymphocytes 
(TILs), activated cytotoxic T lymphocytes (granzyme B+) have 
an antitumor effect, while regulatory T lymphocytes [forkhead 
box P3 (Foxp3)+] suppress the antitumor immune response. 
The aim of the present study was to investigate the possible 
associations between TIL subsets and survival outcomes in 
patients with left‑sided pancreatic ductal adenocarcinoma 
(PDAC). From January 2000 to December 2008, 30 patients 
who underwent curative distal pancreatectomy without 
neoadjuvant chemoradiotherapy due to left‑sided PDAC were 
enrolled in the present study. TIL subsets were enumerated 
by immunohistochemical staining for cluster of differentiation 
(CD)3, CD4, CD8, Foxp3 and granzyme B in the intra‑tumoral 
areas of tissue blocks. Patients were divided into two groups 
according to the median value of the absolute counts and 
relative ratios of TIL subsets. In the univariate analysis, age, 
gender, tumor size, nodal stage, tumor differentiation and 
lymphovascular/perineural invasion were not significantly 
associated with survival outcome. However, low levels of 
preoperative cancer antigen (CA) 19‑9 were associated with a 
longer overall survival (OS), although the association was not 
significant (37 vs. 18 months; P=0.061). A high level of gran-
zyme B+ was associated with enhanced disease‑free survival 
(DFS) (25 vs. 10 months; P=0.023), and a low Foxp3+/gran-
zyme B+ ratio was associated with a favorable prognosis in 
terms of DFS (25 vs. 8 months; P=0.008) and OS (47 vs. 
17 months; P=0.003). In the multivariate analysis, the ratio 
of Foxp3+/granzyme B+ was an independent prognostic factor 
for determining DFS [Exp(B), 3.060; 95% confidence interval 
(CI), 1.259‑47.436; P=0.014] and OS [Exp(B), 3.580; 95% CI, 
1.460‑8.780; P=0.005]. Among the clinicopathological factors, 
low levels of CA 19‑9 were significantly associated with a low 
Foxp3+/granzyme B+ ratio (P=0.016). The results of the present 
study suggested that a low Foxp3+/granzyme B+ ratio may be 
useful for predicting a good prognosis in surgically resected 
left‑sided PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a fatal cancer 
with an overall 5‑year survival rate of <5%. Surgical treatment 
has the most favorable outcome, with a 5‑year survival rate 
of ~20%; however, only 15‑20% of patients are candidates 
for surgical resection (1,2). Standard treatment modalities, 
including chemotherapy and chemoradiotherapy, have been 
shown to be ineffective for improving survival in patients 
with pancreatic cancer (1,2). Therefore, novel treatments are 
urgently required for this devastating disease.
Lymph node metastasis, a high tumor grade, a large tumor 
size, lymphovascular invasion, perineural invasion, a high level 
of preoperative cancer antigen (CA) 19‑9, persistently elevated 
postoperative levels of CA 19‑9 and positive margins of resec-
tion are typically considered the main prognostic factors for 
PDAC (2‑5). In addition to clinicopathological features, the 
tumor‑specific host immune response has been reported to have 
a crucial role in disease‑related survival outcomes for numerous 
types of cancers (6‑15). Among the parameters representing 
tumor‑specific immune function, tumor infiltrating lympho-
cytes (TILs) are often observed in resected cancer tissue and 
are thought to participate in the host immune response against 
cancer (16). Interactions between the tumor microenvironment 
and the immune system significantly affect cancer development 
and progression (17). TILs are considered prognostic factors 
because they represent local host antitumor immunity (16,17).
TILs consist of functionally distinct subsets, including 
the antitumor effectors, CD8+ T lymphocytes and CD4+ 
helper T lymphocytes, which are associated with a favorable 
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prognosis (7). Conversely, regulatory T lymphocytes (Tregs) 
suppress the antitumor immune response and have been 
shown to adversely affect patient survival (6,9,13,14,18). The 
forkhead/winged helix transcription factor, forkhead box P3 
(Foxp3), which is genetically defective in an autoimmune and 
inflammatory syndrome in humans and mice, is specifically 
expressed in naturally arising CD4+ Tregs (19). Tregs weaken 
host antitumor immunity by suppressing T‑cell proliferation, 
antigen presentation and cytokine production (20).
A subset of TILs has been identified in PDAC (21); however, 
the relationship between the TILs and patient prognosis is 
largely unexplored. To evaluate the prognostic value of TILs 
in PDAC, the present study constrained the investigation to 
left‑sided PDAC, as some cases of cancer of the pancreatic 
head cannot be differentiated from distal bile duct, ampulla 
of Vater or duodenal cancers. The present study aimed to 
evaluate the association between TILs in surgically resected 
left‑sided PDAC and patient outcomes.
Materials and methods
Patients. To avoid potential contamination with other 
periampullary cancers, such as distal bile duct, ampulla of 
Vater and duodenal cancers, only left‑sided pancreatic cancers 
were considered. A total of 30 patients who underwent a cura-
tive distal pancreatectomy due to left‑sided PDAC at Severance 
Hospital, Yonsei University College of Medicine (Seoul, Korea) 
between January 2000 and December 2008 were enrolled in 
the present study. In addition, paraffin‑embedded tissue blocks 
from the patients were included in the TIL analysis. The 
present study retrospectively analyzed patient demographics, 
histopathological findings and survival outcomes. Follow‑up 
was completed on May 30, 2012. Patients who received neoad-
juvant chemotherapy or chemoradiotherapy, or had another 
primary tumor, were excluded from the study. Overall survival 
(OS) time was defined as the interval between surgery and 
death, or between surgery and the last observation of surviving 
patients. The disease‑free survival (DFS) time was defined 
as the interval between surgery and recurrence. Data were 
censored at the last follow‑up for living patients. This study 
was approved by the Institutional Review Board of Severance 
Hospital, Yonsei University college of Medicine.
Immunohistochemical (IHC) staining and quantification 
of TIL subsets. IHC staining for TILs was performed as 
described previously (11). Briefly, paraffin‑embedded PDAC 
tissue sections at a thickness of 4‑µm were deparaffinized in 
xylene and rehydrated in decreasing concentrations of ethanol. 
Antigen retrieval was performed in citrate buffer in a micro-
wave oven. Endogenous peroxidase activity was blocked by 
incubating the tissues with 3% hydrogen peroxide in methanol 
for 5 min. The sections were then incubated for 60 min at 
room temperature with primary monoclonal antibodies 
against cluster of differentiation (CD)3 (cat. no. RM‑9107‑S; 
1:100; Lab Vision Corporation, Fremont, CA, USA), CD4 
(cat. no. NCL‑L‑CD4‑1F6; 1:100; Novocastra™ Primary Anti-
bodies; Leica Microsystems, Ltd., Milton Keynes, UK), CD8 
(cat. no. IS62330; 1:100; Dako, Glostrup, Denmark), Foxp3 
(cat. no. ab20034; 1:100; Abcam, Cambridge, UK), and gran-
zyme B (cat. no. MS‑1157‑S;1:100; Lab Vision Corporation), 
which were used to identify total numbers of T lymphocytes, 
helper T lymphocytes, cytotoxic T lymphocytes (CTLs), Tregs 
and activated CTLs, respectively. After washing the sections 
twice with 0.05 mol/l Tris‑buffered saline containing 0.2% 
Tween‑20, the sections were incubated with horseradish perox-
idase‑conjugated secondary antibody (cat. no. K5007; ready 
to use; Dako EnVision® Detection system; Dako), followed 
by development with diaminobenzidine and counterstaining 
with hematoxylin. Normal human tonsil tissue obtained from 
a healthy volunteer was used as the positive control. The nega-
tive control for immunostaining was prepared by incubating 
tissue sections without primary antibody, according to a 
previous study (11).
IHC staining was quantified by two experienced 
pathologists who were blinded to the patient data. Three 
intense foci of staining in the tumor sections were selected 
and four high‑power fields (magnification, x400) from each 
slide were selected for calculation of the IHC staining results. 
Fields with necrosis or hemorrhage in the tumor portion were 
avoided. The median value of positively stained cells in each 
part was recorded. Using the absolute counts and relative 
ratios of lymphocytes stained by each antibody (CD3, CD4, 
CD8, Foxp3 and granzyme B; Fig. 1), the patients were divided 
into low and high groups.
Statistical analysis. All statistical analyses were performed 
with SPSS 20.0 software (IBM SPSS, Armonk, NY, USA). 
Categorical data were compared using χ2 or Fisher's exact 
tests. Absolute counts of TIL subsets and the relative ratios 
between two different TIL subsets were dichotomized in the 
survival analysis using cut‑off values derived by the median, 
as described previously (6,10,11,22). OS and DFS times were 
calculated using the Kaplan‑Meier method and significance 
was evaluated using the log‑rank test. Cox proportional hazard 
models were used for univariate and multivariate survival 
analysis. P<0.05 was considered to indicate a statistical signifi-
cance.
Results
Patient demographics. A total of 54 patients underwent 
curative distal pancreatectomy with or without splenectomy 
for left‑sided PDAC. Among them, 7 patients who under-
went neoadjuvant chemoradiotherapy were excluded. 
Paraffin‑embedded tissue blocks were not available for 
9 patients and the qualities of the paraffin‑embedded tissue 
blocks were not good for 8 patients. Therefore, 30 patients 
were enrolled in this study. The mean age of the enrolled 
patients was 62.4±8.9 years and 21 patients (70%) were male. 
The mean operation time was 327±190 min. Combined organ 
resection was performed in 8 patients (26.7%), and an intra-
operative transfusion was required in 9 patients (30%). The 
mean tumor size was 3.9±1.5 cm. The pathological T stage was 
T2 in 3 patients (10%), T3 in 25 patients (83.3%) and T4 in 
2 patients (6.7%); the pathological N1 stage was observed in 
13 patients (43.3%). Lymphovascular invasion and perineural 
invasion were observed in 8 patients (26.7%) and 11 patients 
(36.7%), respectively. In terms of tumor differentiation, there 
were 7 well‑differentiated, 20 moderately‑differentiated 
and 2 poorly‑differentiated tumors, as well as 1 case of an 
ONCOLOGY LETTERS  12:  4477-4484,  2016 4479
undifferentiated tumor. Resection margin status was R0 in 
27 patients, R1 in 1 patient and R2 in 2 patients. The median 
duration of follow‑up was 23 months (range, 5‑94 months).
Survival outcomes. Table I shows survival outcomes based 
on a univariate analysis according to the clinicopatho-
logical parameters and operative findings. No factors were 
significantly predictive of DFS or OS. However, low levels of 
preoperative CA 19‑9 were associated with a longer OS, with 
a marginal statistical significance (37 vs. 18 months; P=0.061).
Table II shows survival outcomes based on the univariate 
analysis according to the TIL subsets. High levels of gran-
zyme B+ TILs were significantly related to a longer DFS time 
(25 vs. 10 months; P=0.023), and a low Foxp3+/granzyme B+ 
ratio was significantly associated with a favorable DFS 
time (25 vs. 8 months; P=0.008) and OS (47 vs. 17 months; 
P=0.003). High levels of CD4+ were marginally related to good 
DFS (25 vs. 8 months; P=0.063). In the multivariate survival 
analysis, the ratio of Foxp3+/granzyme B+ was an indepen-
dent prognostic factor for determining DFS [Exp(B), 3.060; 
95% confidence interval (CI), 1.259‑7.436; P=0.014) and OS 
[Exp(B), 3.580; 95% CI, 1.460‑8.780; P=0.005) (Table III and 
Fig. 2).
Association between TIL subsets and clinicopathological 
factors. Among the clinicopathological factors, age, gender, 
tumor size, pathological nodal stage, combined organ resection, 
lymphovascular invasion, perineural invasion and transfusion 
were not associated with TIL subsets (CD4+, granzyme B+ and 
Foxp3+/granzyme B+). However, low levels of CA 19‑9 were 
significantly associated with a low Foxp3+/granzyme B+ ratio 
(P=0.016; Table IV).
Discussion
The present study demonstrated the clinical impact of TILs 
in left‑sided PDAC. Although lymph node metastasis, a high 
tumor grade, a large tumor size, lymphovascular invasion, 
perineural invasion, high levels of preoperative CA19‑9, 
persistently elevated postoperative CA19‑9 levels and posi-
tive margins of resection are typically considered prognostic 
factors for pancreatic cancer (2‑5), none were significantly 
correlated with DFS and OS in the present study. Instead, the 
ratio of Foxp3+/granzyme B+ was an independent prognostic 
factor in a multivariate analysis and low levels of CA19‑9 were 
associated with a low Foxp3+/granzyme B+ ratio, despite the 
small sample size.
Previous studies have reported that the host immune 
response to tumors has a critical role in disease‑associated 
survival outcomes (6‑15), suggesting that host immune factors 
may offer a useful tool for predicting prognosis (23). Although 
the status of peripheral blood lymphocytes has been reported 
as a prognostic factor (24), TILs in resected cancer specimens 
are thought to be a more reliable measure of the host immune 
Figure 1. Immunohistochemical staining of tumor‑infiltrating T lymphocytes. (A) After reviewing the tissue sections, three intense foci of staining were 
selected (magnification, x12). Immunohistochemical detection of (B) CD3+ T lymphocytes, (C) CD4+ helper T lymphocytes, (D) CD8+ cytotoxic T lympho-
cytes, (E) forkhead box P3+ regulatory T lymphocytes and (F) granzyme B+ activated cytotoxic T lymphocytes in consecutive sections (magnification, x400). 
CD, cluster of differentiation. 
  A   B
  C   D
  E   F
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response to cancer (16,23,25). TILs consist of functionally 
distinct subsets. Tumor‑infiltrating CD8+ CTLs and CD4+ 
helper T lymphocytes operate as antitumor effectors and 
are associated with a favorable prognosis (7). Activated 
CD8+ T‑cells attack tumor cells presenting tumor‑associated 
antigens via the peptide/major histocompatibility complex 
class I on the tumor cell surface (26,27). Activated CD8+ 
CTLs express granzyme B on their surface (22,28). CD4+ 
T‑cells have a central role in initiating and maintaining the 
host immune response against cancer through numerous 
mechanisms. CD4+ T‑cells provide crucial help to the 
priming of CD8+ T‑cells via activation of antigen‑presenting 
cells. Furthermore, CD4+ T‑cells secrete cytokines required 
for maintaining CD8+ T‑cell function and proliferation, and 
can also inhibit tumor growth directly or indirectly. In addi-
tion, CD4+ T‑cells promote B‑cell activation (29,30). Tregs, 
which make up a small fraction (5‑6%) of the overall CD4+ 
T‑cell population, reduce the antitumor immune response 
by suppressing effector T‑cells and the production of several 
immunosuppressive cytokines, including interleukin‑10 and 
transforming growth factor‑β (31,32). Tregs have been shown 
to adversely affect patient survival (6,9,13,14,18). The role 
of Tregs in PDAC is well‑understood, and circulating Tregs 
and PDAC tissue‑specific Treg cells are significantly higher 
in patients with pancreatic cancer compared with healthy 
controls (24,33‑37). Furthermore, the presence of Tregs in 
tumor tissue correlates with the stage and progression of 
pancreatic cancer (24,33‑37).
Table I. Univariate survival analysis according to clinicopathological and operative findings.
 Disease‑free survival Overall survival
 -------------------------------------------------------------------- -------------------------------------------------------------------
Characteristic Months (median) P‑value Months (median) P‑value
Age, years  0.273  0.261
  <59 (n=13) 11  18 
  ≥59 (n=17) 12  29 
Gender  0.483  0.419
  Male (n=21) 12  22 
  Female (n=9) 10  23 
CA 19‑9, U/mla  0.152  0.061
  ≤109 (n=15) 13  37 
  >109 (n=14) 7  18 
Tumor size, cm  0.404  0.467
  <3.5 (n=15) 12  35 
  ≥3.5 (n=15) 8  18 
N stage  0.219  0.137
  N0 (n=17) 12  35 
  N1 (n‑13) 8  18 
Combined organ resection  0.100  0.480
  No (n=22) 12  25 
  Yes (n=8) 7  20 
Differentiation  0.178  0.219
  Well (n=7) 25  37 
  Moderate (n=20) 10  20 
  Poor (n=2) 3  9 
  Undifferentiated (n=1) 7  21 
Lymphovascular invasionb  0.799  0.685
  No (n=20) 11  22 
  Yes (n=8) 7  25 
Perineural invasionb  0.682  0.438
  No (n=17) 12  20 
  Yes (n=11) 10  25 
Transfusion  0.084  0.091
  No (n=21) 12  35 
  Yes (n=9) 7  18 
aData unavailable for 1 patient. bData unavailable for 2 patients. CA 19‑9, cancer antigen 19‑9.
 
ONCOLOGY LETTERS  12:  4477-4484,  2016 4481
Fukunaga et al (25) reported that the presence of CD4+ 
T‑cells together with CD8+ T‑cells was negatively corre-
lated with tumor depth and tumor‑node‑metastasis stage in 
pancreatic cancer. Furthermore, in multivariate analyses, 
they demonstrated that a CD4+/CD8+ status was an indepen-
dent favorable prognostic factor (25). Ino et al (35) reported 
Table II. Univariate survival analysis according to TIL subset counts.
 Disease‑free survival Overall survival
 ---------------------------------------------------------------------- ---------------------------------------------------------------------
TIL subset Months (median) P‑value Months (median) P‑value
Absolute count
  CD3+  0.290  0.643
    Low (<256, n=15) 11  21 
    High (≥256, n=15) 13  25 
  CD4+  0.063  0.164
    Low (<160, n=15) 8  18 
    High (≥160, n=15) 25  37 
  CD8+  0.116  0.208
    Low (<115, n=15) 8  18 
    High (≥115, n=15) 13  35 
  Granzyme B+  0.023a  0.084
    Low (<24, n=15) 10  18 
    High (≥24, n=15) 25  37 
  Foxp3+  0.538  0.603
    Low (<28, n=15) 12  22 
    High (≥28, n=15) 10  23 
Relative ratio
  Foxp3+/CD3+  0.408  0.421
    Low (<0.111, n=15) 13  29 
    High (≥0.111, n=15) 10  20 
  Foxp3+/CD4+  0.104  0.094
    Low (<0.169, n=15) 14  37 
    High (≥0.169, n=15) 10  18 
  Foxp3+/CD8+  0.173  0.124
    Low (<0.026, n=15) 13  37 
    High (≥0.026, n=15) 10  18 
  Foxp3+/granzyme B+  0.008a  0.003a
    Low (<0.110, n=15) 25  47 
    High (≥0.110, n=15) 8  17 
aP<0.05. CD, cluster of differentiation; Foxp3, forkhead box P3; TIL, tumor‑infiltrating lymphocyte.
 
Table III. Multivariate survival analysis according to TIL subset counts.
 Disease‑free survival Overall survival
 ----------------------------------------------------------------------- ----------------------------------------------------------------------
TIL Exp(B) 95% CI P‑value Exp(B) 95% CI P‑value
CD4+ (low vs. high) 1.738 0.725‑4.167 0.215 1.617 0.684‑3.825 0.273
Granzyme B+ (low vs. high) 1.405 0.485‑4.068 0.531 0.979 0.331‑2.895 0.970
Foxp3+/granzyme B+ (high vs. low) 3.060 1.259‑7.436 0.014a 3.580 1.460‑8.780 0.005a
aP<0.05. CD4, cluster of differentiation 4; 95% CI, 95% confidence interval; Foxp3, forkhead box P3; TIL, tumor‑infiltrating lymphocyte.
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Figure 2. Kaplan‑Meier analysis of (A) disease‑free survival and (B) overall survival according to the Foxp3+/granzyme B+ ratio (low vs. high). The low 
Foxp3+/granzyme B+ ratio group showed favorable survival outcomes in terms of disease‑free (P=0.014) and overall (P=0.005) survival. Foxp3, forkhead 
box P3; GNZB, granzyme B.
  A   B
Table IV. Association between tumor‑infiltrating lymphocyte subsets and clinicopathological factors.
 CD4+ Granzyme B+ Foxp3+/granzyme B+
 ------------------------------------------------------  -----------------------------------------------------  -------------------------------------------------------
Characteristic Low High P‑value Low High P‑value Low High P‑value
Age, years    0.713   0.269   0.713
  <59 (n=13) 6 (40.0) 7 (46.7)  8 (53.3) 5 (33.3)  7 (46.7) 6 (40.0)
  ≥59 (n=17) 9 (60.0) 8 (53.3)  7 (46.7) 10 (66.7)  8 (53.3) 9 (60.0) 
Gender   0.427   0.427   1.000
  Male (n=21) 9 (60.0) 12 (80.0)  9 (60.0) 12 (80)  10 (66.7) 11 (73.3) 
  Female (n=9) 6 (40.0) 3 (20.0)  6 (40.0) 3 (20)  5 (33.3%) 4 (26.7) 
Tumor size, cm    0.715   0.715   0.715
  <3.5 (n=15) 8 (53.3) 7 (46.7)  7 (46.7) 8 (53.3)  8 (53.3) 7 (46.7) 
  ≥3.5 (n=15) 7 (46.7) 8 (53.3)  8 (53.3) 7 (46.7)  7 (46.7) 8 (53.3) 
Nodal stage    0.713   0.713   0.269
  N0 (n=17) 8 (53.3) 9 (60.0)  8 (53.3) 9 (60.0)  10 (66.7) 7 (46.7) 
  N1 (n=13) 7 (46.7) 6 (40.0)  7 (46.7) 6 (40.0)  5 (33.3) 8 (53.3) 
Combined resection    1.000   1.000   0.682
  No (n=22) 11 (73.3) 11 (73.3)  11 (73.3) 11 (73.3)  12 (80.0) 10 (66.7) 
  Yes (n=8) 4 (26.7) 4 (26.7)  4 (26.7) 4 (26.7)  3 (20.0) 5 (33.3) 
Lymphovascular invasionb   0.678   1.000   1.000
  No (n=20) 11 (78.6) 9 (64.3)  11 (73.3) 9 (69.2)  9 (69.2) 11 (73.3) 
  Yes (n=8) 3 (21.4) 5 (35.7)  4 (26.7) 4 (46.2)  4 (30.8) 4 (26.7) 
Perineural invasionb   0.699   0.488   0.934
  No (n=17) 8 (57.1) 9 (64.3)  10 (66.7) 7 (53.3)  8 (61.5) 9 (60.0) 
  Yes (n=11) 6 (42.9) 5 (35.7)  5 (33.3) 6 (46.2)  5 (38.5) 6 (40.0) 
Transfusion   1.000   1.000   1.000
  No (n=21) 11 (73.3) 10 (66.7)  11 (73.3) 10 (66.7)  11 (73.3) 10 (66.7) 
  Yes (n=9) 4 (26.7) 5 (33.3)  4 (26.7) 5 (33.3)  4 (26.7) 5 (33.3) 
CA 19‑9, U/mlc    0.573   0.356   0.016a
  ≤109 (n=15) 8 (57.1) 7 (46.7)  6 (42.9) 9 (60.0)  11 (73.3) 4 (28.6) 
  >109 (n=14) 6 (42.9) 8 (53.3)  8 (57.1) 6 (40.0)  4 (26.7) 10 (71.4) 
Data are presented as n (%). aP<0.05. bData unavailable for 2 patients. cData unavailable for 1 patient. CA 19‑9, cancer antigen 19‑9; CD4, 
cluster of differentiation 4; Foxp3, forkhead box P3.
 
ONCOLOGY LETTERS  12:  4477-4484,  2016 4483
that higher levels of tumor‑infiltrating CD4+ and CD8+ 
T‑cells were significantly associated with a longer survival 
in patients with PDAC. In the present study, patients with 
higher CD4+ T‑cell counts had longer DFS and OS times, 
but the results did not reach statistical significance. High 
CD8+ T‑cell counts were also associated with longer DFS 
and OS times, but the trend also failed to reach statistical 
significance.
Granzyme B is exclusively expressed on the surface of 
activated CD8+ CTLs (38). Activated CTLs (granzyme B+) 
have been identified as a favorable prognostic factor in various 
cancers (22,28,39‑41); however, their role in PDAC is unknown. 
In the present study, patients with high granzyme B+ CTL 
counts showed significantly improved DFS (25 vs. 10 months; 
P=0.023) and longer OS in the univariate survival analysis 
(37 vs. 18 months; P=0.084).
The balance between effector T‑cells (CD4+, CD8+ and gran-
zyme B+ T‑cells) and Tregs may more effectively reflect prognosis 
than absolute counts alone. A ratio of high effector cell‑to‑low 
Treg density has been reported as a promising independent 
predictor for prognosis in various tumors (9,11,14,22,23,42). 
Accordingly, the present study analyzed the ratios of 
Foxp3+/CD4+, Foxp3+/CD8+ and Foxp3+/granzyme B+ as prog-
nostic factors on the basis that they were more representative of 
the biological characteristics of TILs. The univariate survival 
analysis according to the relative ratios of TIL subsets indicated 
that patients with a low ratio of Foxp3+/granzyme B+ had a 
significantly improved DFS (25 vs. 8 months; P=0.008) and 
OS (47 vs. 17 months; P=0.003). In the multivariate survival 
analysis, a low Foxp3+/granzyme B+ ratio remained a significant 
independent prognostic marker with a higher hazard ratio for 
DFS [Exp(B), 3.060; 95% CI, 1.259‑7.436; P=0.014] and OS 
[Exp (B), 3.580; 95% CI, 1.460‑8.780; P=0.005).
The present study was limited by the small number of 
patients, particularly since we did not observe any statistically 
significant differences, even for conventional prognostic factors. 
However, despite the small size, the present study demonstrated 
that a low Foxp3+/granzyme B+ ratio predicted a significantly 
improved prognosis. Further studies with larger sample sizes are 
required to clarify the prognostic meaning of TILs in associa-
tion with other clinicopathological parameters. This study also 
showed that low levels of CA19‑9 were significantly associated 
with a low Foxp3+/granzyme B+ ratio. 
In conclusion, the present study demonstrated that a low 
Foxp3+/granzyme B+ ratio was an independent favorable prog-
nostic marker following surgical resection of left‑sided PDAC. 
This immunological parameter may be useful for stratifying 
patients and planning adjuvant treatment.
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